WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops
anticancer therapeutics using its Targeted Antibody Payload (TAP)
technology and antibody expertise, today announced that Daniel Junius,
President and CEO, will present at the upcoming 31st Annual
J.P. Morgan Healthcare Conference in San Francisco. The presentation is
scheduled for 8:00 am PT on January 7, 2013 and will include information
about IMGN289, which is on track to become the fourth wholly owned
ImmunoGen compound to advance into clinical testing.
A webcast of this presentation will be accessible live through the
"Investor Information" section of the Company's website, www.immunogen.com;
a replay of the presentation will be available at the same location for
two weeks.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its TAP
technology together with the Company's expertise in monoclonal
antibodies and tumor biology. A TAP compound uses a tumor-targeting
monoclonal antibody to deliver one of ImmunoGen's purpose-developed
cancer-killing agents specifically to tumor cells. Ten TAP compounds are
now in clinical testing, of which three are wholly owned by the Company.
Marketing applications for trastuzumab emtansine (T-DM1), the most
advanced compound using ImmunoGen's TAP technology, are under review in
the US and Europe. Roche is developing this compound globally under an
agreement between ImmunoGen and Genentech, a member of the Roche Group.
More information about ImmunoGen can be found at www.immunogen.com.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Barbara Yates, 781-258-6153
Source: ImmunoGen, Inc.
News Provided by Acquire Media